Skip to main content

Acrivon Therapeutics, Inc.

corporate_fare Company Profile

Acrivon Therapeutics, Inc.

ACRV·NASDAQ·Life Sciences·CIK 0001781174

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines. The company utilizes its proprietary Generative Phosphoproteomics Acrivon Predictive Precision Proteomics, or AP3, platform. This platform is designed to quantify compound-specific, drug-regulated pathway activity levels within intact cells in an unbiased manner, generating terabytes of proprietary data and providing rapid, actionable insights. The name "Acrivon" is derived from Greek for "accurate" or "precise," reflecting the platform's ability to match therapies with patients who will benefit. Acrivon's approach aims to overcome the limitations of genetics-based precision medicine, which currently addresses less than 10% of cancer patients with easily identifiable genetic mutations. The AP3 platform is engineered to measure compound-specific effects on the entire tumor cell protein, signaling network, and drug-induced resistance mechanisms in an unbiased, modality, and disease-agnostic way. This proteomics-based approach directly measures critical tumor-driving pathways, independent of underlying genetic alterations. Acrivon believes its method is applicable across drug development stages and therapeutic modalities, not limited to cancers driven by single gene driver mutations or susceptible to a synthetic lethal approach. The company believes its method is broadly applicable to the majority of cancers, particularly solid tumors, where genetics-based approaches have often been insufficient to identify patient responders. The AP3 platform is designed to enable the therapeutic addressing of a much larger percentage of tumors by using agents attuned to specific biochemical signaling pathways.

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ACRV at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 9 rated 8 or above. Recent SEC coverage for ACRV spans 8-K, S-3, 10-Q, DEFA14A.

Recent high-impact activity:

  • Acrivon Presents ACR-2316 Phase 1/2 Data: Confirmed CR in Lung Cancer, No DLTs at Selected Doses
  • Acrivon Files New $300M Shelf Days After Disclosing Going-Concern Doubt
  • Acrivon Q3 Loss Narrows to $17.9M; $77.8M Cash Funds Operations Into Q4 2027
  • Acrivon Q3 2026: $77.8M Cash, but Substantial Going-Concern Doubt
  • Acrivon Details ACR-525 JAK1 Data and EoE Phase 2 Plan at R&D Event

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$77.91M
Diluted EPS
-$2.02
Op. Cash Flow
-$63.66M
Free Cash Flow
-$65.33M
Operating Income
-$84.11M
Cash & Equivalents
$41.5M
Debt / Equity
0.00×
Shares Outstanding
31.65M sh
Source: 10-K · filed 2026-03-19 · accession 0001193125-26-115123

Short Interest & Short Volume

11.37 days to cover

FINRA reported short interest of 1,804,674 shares in ACRV as of the October 30, 2026 settlement, a 3.9% increase from the prior period — about 11.4 days to cover at its recent average daily volume. On November 20, 2026, 45.7% of ACRV volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,804,674 shares as of October 30, 2026
Change vs prior period▲ 3.9%
Days to cover11.37 at avg daily volume of 158,681
Daily short volume (FINRA facilities)45.7% of 936,661 shares on November 20, 2026
5-day average short volume51.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for ACRV, detected from its recent SEC filings.

1 shelf registration

New $300M Universal Shelf Filed · Most Capacity Is Rolled Forward

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$1.16 +0.87% today
52-week range · as of 2026-11-20 $0.9709 – $3.56
Market cap
$49.35M
Volume
1.3M (4.9× avg)
3-mo avg 266.9K
Live data · 2026-11-22 09:04 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ACRV - Latest Insights

ACRV
Nov 20, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.15
Real-time Price: $1.16 info
Change: +$0.010 (+0.87%) info
Market Cap: $49.348M info
ACRV
Nov 16, 2026, 5:11 PM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.43
Real-time Price: $1.16 info
Change: -$0.2731 (-19%) info
Market Cap: $49.348M info
ACRV
Nov 16, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.45
Real-time Price: $1.16 info
Change: -$0.290 (-20%) info
Market Cap: $49.348M info
ACRV
Nov 16, 2026, 4:03 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.45
Real-time Price: $1.16 info
Change: -$0.290 (-20%) info
Market Cap: $49.348M info
ACRV
Nov 10, 2026, 4:55 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $1.16 info
Change: -$0.440 (-28%) info
Market Cap: $49.348M info
ACRV
Nov 06, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $1.16 info
Change: -$0.440 (-28%) info
Market Cap: $49.348M info
ACRV
Nov 06, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.57
Real-time Price: $1.16 info
Change: -$0.410 (-26%) info
Market Cap: $49.348M info
ACRV
Aug 12, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.72
Real-time Price: $1.16 info
Change: -$0.560 (-33%) info
Market Cap: $49.348M info
ACRV
Aug 05, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.57
Real-time Price: $1.16 info
Change: -$0.410 (-26%) info
Market Cap: $49.348M info
ACRV
Jun 17, 2026, 5:28 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.52
Real-time Price: $1.16 info
Change: -$0.360 (-24%) info
Market Cap: $49.348M info
ACRV
May 22, 2026, 4:05 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $1.75
Real-time Price: $1.16 info
Change: -$0.590 (-34%) info
Market Cap: $49.348M info
ACRV
May 13, 2026, 4:12 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.98
Real-time Price: $1.16 info
Change: -$0.820 (-41%) info
Market Cap: $49.348M info
ACRV
May 13, 2026, 4:10 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.97
Real-time Price: $1.16 info
Change: -$0.810 (-41%) info
Market Cap: $49.348M info
ACRV
Apr 23, 2026, 4:29 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.90
Real-time Price: $1.16 info
Change: -$0.740 (-39%) info
Market Cap: $49.348M info
ACRV
Apr 17, 2026, 4:00 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.78
Real-time Price: $1.16 info
Change: -$0.620 (-35%) info
Market Cap: $49.348M info
ACRV
Mar 19, 2026, 7:10 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $1.62
Real-time Price: $1.16 info
Change: -$0.460 (-28%) info
Market Cap: $49.348M info
ACRV
Mar 17, 2026, 5:54 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.69
Real-time Price: $1.16 info
Change: -$0.530 (-31%) info
Market Cap: $49.348M info
ACRV
Mar 03, 2026, 3:03 PM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.73
Real-time Price: $1.16 info
Change: -$0.565 (-33%) info
Market Cap: $49.348M info
ACRV
Mar 02, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.53
Real-time Price: $1.16 info
Change: -$0.370 (-24%) info
Market Cap: $49.348M info
ACRV
Jan 16, 2026, 4:02 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $2.08
Real-time Price: $1.16 info
Change: -$0.920 (-44%) info
Market Cap: $49.348M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets